In an email to The Center for Biosimilars®, Mylan confirmed that it will launch its biosimilar pegfilgrastim at a wholesale acquisition cost (WAC) of $4175 per syringe, a price that reflects a 33% discount to the WAC of Amgen’s reference product, Neulasta.
In addition to being the first drug developer to receive FDA approval for a pegfilgrastim biosimilar, Mylan plans to launch its product, the newly approved Fulphila, at a deeper discount to its reference than any other first biosimilar launched in the US marketplace.
In an email to The Center for Biosimilars®, Mylan confirmed that it will launch its biosimilar pegfilgrastim at a wholesale acquisition cost (WAC) of $4175 per syringe, a price that reflects a 33% discount to the WAC of Amgen’s reference product, Neulasta.
Mylan’s strategy of beginning with such a substantial discount may reflect lessons learned from Celltrion and Pfizer’s launch of Inflectra. When the first biosimilar infliximab, referencing Remicade, launched at just a 15% discount to the reference’s WAC (following the example of Sandoz’s filgrastim biosimilar, Zarxio, which launched at a 15% discount to the reference Neupogen’s WAC), it struggled to gain market share.
With both the shallow discount and the reference product sponsor, Johnson & Johnson (J&J), offering incentives to continue to use the reference drug, payers saw little financial reason to undertake a change to the biosimilar. Pfizer has decried J&J’s strategies as anticompetitive in nature, and has filed suit against the Remicade maker. (J&J has countered, however, that Pfizer has not demonstrated the value of its product or a willingness to compete in the marketplace.)
With Inflectra already struggling to gain a foothold in the marketplace, Merck and Samsung Bioepis’ Renflexis, the second infliximab biosimilar to enter the US market, has seen little uptake despite its deeper launch discount of 35%.
Whether Mylan’s choice to offer such a substantial discount for its pegfilgrastim will help to overcome the hurdles of slow US biosimilar uptake remains to be seen, as does Mylan and partner Biocon’s strategy for pricing their other FDA-approved biosimilar, Ogivri, a trastuzumab product referencing Herceptin.
No launch date has been revealed for either of the Mylan—Biocon biosimilars, but the partnership made strides toward an eventual launch this month when it received the European Union’s Good Manufacturing Practice Certification for its biosimilar production plant in Bangalore, India. Manufacturing practices at the site have been called into question numerous times, most recently in May 2018, when the FDA issued a Form 483 related to 7 observations made during a preapproval inspection. In June 2018, Biocon confirmed that it had received an Establishment Inspection Report from the FDA, and that the inspection of the facility is now closed.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.
Eye on Pharma: Canadian Aflibercept Settlement; Sandoz Acquires Cimerli; Payer Chooses Cyltezo
March 6th 2024Biocon Biologics settled with the maker of Eylea (aflibercept), announcing a launch date for its biosimilar competitor in Canada; Sandoz has officially acquired Cimerli, a ranibizumab biosimilar; AARP Medicare Rx from United Healthcare has added Cyltezo (adalimumab-adbm) and removed the originator (Humira) from its formulary.